– UK, Oxford – NIOX Group plc (LON: NIOX), a medical device company focused on point-of-care asthma diagnosis and management, announced the appointment of Robert Naylor to its Board as Non-Executive Director, with immediate effect.
Robert Naylor will also be Chair of the Audit and Risk Committee.
About Robert Naylor
Robert Naylor has over 25 years of experience in capital markets specializing in healthcare and investment companies and is currently CEO of Intuitive Investments Group plc, an investment company that is quoted on the Specialist Fund Segment of the London Stock Exchange’s Main Market, providing investors with exposure to a portfolio of fast-growing technology and life sciences businesses. He is Non-Executive Chairman of Hipgnosis Songs Fund Limited, a FTSE 250 company, which is currently subject to a recommended cash offer by Lyra Bidco Limited, a newly-formed company indirectly wholly-owned by investment funds advised by affiliates of Blackstone Inc.
Previously, Robert Naylor was Non-Executive Chairman of Round Hill Music Royalty Fund Limited and oversaw its sale to a company directly owned by Alchemy Copyrights, LLC, trading as Concord. He has also served as a Non-Executive Director of Light Science Technologies Holdings plc, an AIM-quoted controlled environment agriculture company. Earlier in his career, Robert held various positions within JP Morgan Asset Management Limited, Panmure Gordon (UK) Limited, and Cenkos Securities plc. Robert is a qualified chartered accountant, having started his career with Ernst & Young in 1996.
About NIOX
Our mission is to improve asthma diagnosis and management by greater patient access to FeNO testing. Asthma is one of the biggest healthcare issues globally with 340 million sufferers, many of whom are undiagnosed or are misdiagnosed. The Group is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for asthma. Our market-leading device, NIOX VERO®, is increasingly recognized by healthcare professionals as an important tool to improve the diagnosis and management of asthma. NIOX VERO® is also the device of choice by leading clinical research organizations for respiratory studies.
NIOX provides products and services via its direct sales organization and extensive distributor network in 50 countries.
For more information: https://www.niox.com/en/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
